[{"Assets_0_Q2_USD":132559000.0,"CommonStockSharesOutstanding_0_Q2_shares":17225167.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-14998000.0,"NetIncomeLoss_1_Q2_USD":-3304000.0,"NetIncomeLoss_2_Q2_USD":-8334000.0,"StockholdersEquity_0_Q2_USD":106951000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":5592000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":9311000.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20181031","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181214"}]